The Hydroalcoholic Extract of Uncaria tomentosa (Cat's Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Vitro
ABSTRACT: The coronavirus disease 2019 (COVID-19) has become a serious problem for public health since it was identified in the province of Wuhan (China) and spread around the world producing high mortality rates and economic losses. Nowadays, the WHO recognizes traditional, complementary, and alter...
- Autores:
-
Yepes Pérez, Andrés Felipe
Herrera Calderón, Oscar
Oliveros, Cristina A
Flórez Álvarez, Lizdany
Zapata Cardona, María Isabel
Yepes Daza, Lina Marcela
Aguilar Jiménez, Wbeimar
Rugeles López, María Teresa
Zapata Builes, Wildeman
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2021
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/36416
- Acceso en línea:
- https://hdl.handle.net/10495/36416
- Palabra clave:
- Coronavirus
SARS-CoV-2
Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo
Severe acute respiratory syndrome-related coronavirus
Extractos Vegetales
Plant Extracts
Uña de Gato
Cat's Claw
Medicina Tradicional
Medicine, Traditional
Antivirales
Antiviral Agents
Ensayos Clínicos como Asunto
Clinical Trials as Topic
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by/4.0/
| Summary: | ABSTRACT: The coronavirus disease 2019 (COVID-19) has become a serious problem for public health since it was identified in the province of Wuhan (China) and spread around the world producing high mortality rates and economic losses. Nowadays, the WHO recognizes traditional, complementary, and alternative medicine for treating COVID-19 symptoms. Therefore, we investigated the antiviral potential of the hydroalcoholic extract of Uncaria tomentosa stem bark from Peru against SARS-CoV-2 in vitro. The antiviral activity of U. tomentosa against SARS-CoV-2 in vitro was assessed in Vero E6 cells using cytopathic effect (CPE) and plaque reduction assay. After 48 h of treatment, U. tomentosa showed an inhibition of 92.7% of SARS-CoV-2 at 25.0 μg/mL (p < 0.0001) by plaque reduction assay on Vero E6 cells. In addition, U. tomentosa induced a reduction of 98.6% (p=0.02) and 92.7% (p=0.03) in the CPE caused by SARS-CoV-2 on Vero E6 cells at 25 μg/mL and 12.5 μg/mL, respectively. The EC50 calculated for the U. tomentosa extract by plaque reduction assay was 6.6 μg/mL (4.898.85 μg/mL) for a selectivity index of 4.1. The EC50 calculated for the U. tomentosa extract by TCID50 assay was 2.57 μg/mL (1.05-3.75 μg/mL) for a selectivity index of 10.54. These results showed that U. tomentosa, known as cat's claw, has an antiviral effect against SARS-CoV-2, which was observed as a reduction in the viral titer and CPE after 48 h of treatment on Vero E6 cells. Therefore, we hypothesized that U. tomentosa stem bark could be promising in the development of new therapeutic strategies against SARS-CoV-2. |
|---|
